Trials / Completed
CompletedNCT01767636
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor.
Detailed description
PRIMARY OBJECTIVES: I. To determine the efficacy of pazopanib hydrochloride (pazopanib) in non clear cell metastatic renal cell cancer patients as assessed by the overall survival rate at 12 months. SECONDARY OBJECTIVES: I. To determine the rates of best tumor response at the end of the first two treatment cycles of pazopanib in non clear cell metastatic renal cell cancer patients. II. To determine the benefit of pazopanib in increasing progression free survival time. III. To describe toxicity profile of pazopanib in non clear cell metastatic renal cell cancer patients. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 2 years.
Conditions
- Carcinoma of the Collecting Ducts of Bellini
- Chromophobe Renal Cell Carcinoma
- Kidney Medullary Carcinoma
- Kidney Oncocytoma
- Metastatic Renal Cell Cancer
- Papillary Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage IV Renal Cell Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib Hydrochloride | Given PO |
Timeline
- Start date
- 2013-05-16
- Primary completion
- 2019-02-02
- Completion
- 2021-01-20
- First posted
- 2013-01-14
- Last updated
- 2025-03-03
- Results posted
- 2020-04-08
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01767636. Inclusion in this directory is not an endorsement.